@VincentRK I would like to combine good of both regimens. We have reasonable experience with FLAG-VEN with very high CRc rates and lower mortality. Our data are compared with Paradigm cohort
Linvoseltamab yielded impressive response performance in patients with relapsed or refractory systemic light chain #amyloidosis, according to the LINKER-AL2 trial presented at #ASCO26.
📰 Read here: https://t.co/YHs5D1OSvb
📢#lymsm Get all your CLL and BTK inhibitor questions answered in this upcoming @lymphomahub seminar with expert from both sides of the pond.
Link to register: https://t.co/yv7sI9nQen
vTitan medical equipment update: we have been shipping steadily and a big shipment of syringe pumps is getting ready at the factory!
We also have an affordable pump for Thalassemia (vTitan AccuFlow Thala pump) and over a thousand patients have benefited from it.
Our R&D team is working hard on many more products. Our particular focus is on affordability.
vTitan is teaching us a lot about hardware design and manufacturing.
🚨⭐️Wow! What a surprise!
⭐️Deeply honored to receive the Indo-American-Cancer-Association Award at @ASCO#ASCO26 for Outstanding Contributions to Drug Development & Pioneering Advances in Clinical Cancer Research 2026
👉This recognition means so much not just as a personal milestone, but as a reflection of the incredible VILLAGE that makes this work possible
🙏 Mentors who shaped MY thinking + collaborators who challenged & inspired me + Patients who trusted me with their care + friends & family who anchored me through it all
🙏Thank you to the IACA @IACAconnect leadership for this honor @DrSwami_Iyer@Santchawla1 Vinay Jain @jamecancerdoc@BrainTumorDoc@SewantiLimaye #PrecisionOncology🙏 #ASCO26 #IACA #DrugDevelopment #CancerResearch @OncoAlert@oncodaily@OpenMedicineHQ
One of the most rewarding and emotional moments of my career took place at #ASCO2026. In 2015, I started the first-in-human trial of 11-1F4 (now anselamimab), supported by a small FDA grant and @columbiacancer. At the time, the path forward was far from certain. We faced limited funding, strong competition from Prothena’s NEOD001 program, and considerable skepticism from industry given the rarity of AL amyloidosis and the fact that competing programs were already much further advanced in development.
Despite these challenges, we continued to move forward step by step. The phase 1 study demonstrated encouraging results, ultimately leading to the founding and funding of Caelum Biosciences in 2017 and the launch of the subsequent phase 2 and phase 3 studies. Those efforts were later advanced and completed through the commitment and resources of @AlexionCARES and @AstraZenecaUS.
@ASCO I had the privilege of chairing the session when the final phase 3 results where presented by Dr. Wechalekar, which demonstrated a significant overall survival benefit in patients with stage IIIA/IIIB κ AL amyloidosis🙌. Seeing a scientific concept evolve from an investigator-initiated first-in-human study into a positive phase 3 trial is extraordinarily rewarding.
This achievement reflects the dedication of countless patients, supporters🙏@MorieGertz, investigators, research staff, industry partners, and advocates who believed in this program over many years. It is also a powerful reminder of why we do translational research-to transform promising science into therapies that meaningfully improve patients' lives.
#ASCO2026 #ALAmyloidosis @Amyloidosis_ARC@Amyloidosisfdn@AmyloidosisSupp@ISA_Amyloidosis
frontMIND just published after great/streamlined presentation by Dr. Lenz et al showing a 2nd PhIII confirmed PFS over R-CHOP (after POLARIX) and appears as an impressive new/upcoming SOC option in #DLBCL#lymsm#ASCO26@Incyte https://t.co/FJLu11TER9
Thank you @UTMDAnderson . Great to see this important FDA approval for rare cancers the day before ASCO! Truly honored to lead this study with @doctorpemm . Appreciate the tremendous global
collaborators who made it possible!@garciamanero @pistes@ACKoongMDPhD@ChrisRFlowersMD